title: mdm 2 mRNA expression is associated with survival in ovarian cancer.
abstract: Expression of mdm-2 mRNA was measured in 90 ovarian-cancer tissue specimens using the S1 nuclease assay, to investigate a possible association between MDM2 expression and prognosis. mdm-2 mRNA expression was an independent prognostic factor for patients with primary ovarian cancer, FIGO (International Federation of Gynecology and Obstetrics) stages III and IV (n = 57), who all received chemotherapy with carboplatin or cisplatin and cyclophosphamide. Median survival time for patients (FIGO stages III and IV) with no detectable expression of mdm-2 mRNA (n = 14) was 171 days, as compared with 839 days for patients (n = 43) with detectable mdm-2 mRNA (p = 0.0194; log-rank test). However, no association between mdm-2 mRNA expression and survival was observed for patients with FIGO stages I and II who did not receive chemotherapy. mdm-2 expression was not associated with FIGO stage, residual disease, histologic grade and type. Our results suggest that mdm-2, which is known to disrupt p53 function, sensitizes ovarian-cancer cells to cisplatin/cyclophosphamide, possibly by inhibition of p53-mediated G1 cell-cycle arrest and p53-stimulated nucleotide-excision repair.
authors.affiliation: Department of Gynecology and Obstetrics, University of Mainz, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Tanner
authors.forename: J G
authors.initials: JG
authors.lastname: Hengstler
authors.forename: S
authors.initials: S
authors.lastname: Laubscher
authors.forename: R
authors.initials: R
authors.lastname: Meinert
authors.forename: F
authors.initials: F
authors.lastname: Oesch
authors.forename: W
authors.initials: W
authors.lastname: Weikel
authors.forename: P G
authors.initials: PG
authors.lastname: Knapstein
authors.forename: R
authors.initials: R
authors.lastname: Becker
mesh_terms: D016001:Confidence Intervals; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007044:Hysterectomy; D009363:Neoplasm Proteins / Q000096:biosynthesis; D009367:Neoplasm Staging; D009687:Nuclear Proteins; D009852:Omentum / Q000601:surgery; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D010052:Ovariectomy; D011237:Predictive Value of Tests; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis*; D051736:Proto-Oncogene Proteins c-mdm2; D015347:RNA Probes; D012333:RNA, Messenger / Q000032:analysis / Q000096:biosynthesis*; D012008:Recurrence; D018570:Risk Assessment; D015996:Survival Rate; D014158:Transcription, Genetic
chemical_list: D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D015347:RNA Probes; D012333:RNA, Messenger; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2